bluebird bio, Inc. (LON: 0HOH)
London
· Delayed Price · Currency is GBP · Price in USD
8.02
+0.08 (1.01%)
Jan 31, 2025, 5:28 PM BST
bluebird bio Revenue
bluebird bio had revenue of $10.61M USD in the quarter ending September 30, 2024, a decrease of -14.36%. This brings the company's revenue in the last twelve months to $53.12M, up 144.50% year-over-year. In the year 2023, bluebird bio had annual revenue of $29.50M with 720.04% growth.
Revenue (ttm)
$53.12M
Revenue Growth
+144.50%
P/S Ratio
n/a
Revenue / Employee
$141.65K
Employees
375
Market Cap
60.62M GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
bluebird bio News
- 16 days ago - HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws' - Benzinga
- 5 weeks ago - Bluebird Bio (BLUE) Shares Surge Amid Market Activity - GuruFocus
- 5 weeks ago - 2seventy bio: All In On Abecma Multiple Myeloma Treatment - Seeking Alpha
- 7 weeks ago - Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock - Benzinga
- 2 months ago - bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
- 2 months ago - Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels - Business Wire
- 2 months ago - bluebird bio announces 1-for-20 reverse stock split; shares tumble - Seeking Alpha
- 2 months ago - bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire